Curis Inc. (CRIS)
CRIS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1108205/000110820526000043/0001108205-26-000043-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CRIS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001108205 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.4M |
| Net income | -$7.6M |
| Operating income | -$5.7M |
| Net margin | -80.3% |
| Operating margin | -60.5% |
| Revenue growth | -13.4% |
| Cash | $5.1M |
| Total assets | $20.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "In accordance with Financial Accounting Standards Board ( FASB ) Accounting Standards Update ( ASU ) No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the " | 10-Q 2026-11-13 |
| Cash and burn | $5.1M cash; operating cash flow -$7.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | 9,512,232 (2026-11-10); 12,928,853 a year earlier; 5,883,063 three years earlier. 1y figure adjusted for splits (1-for-20 overall); 3y figure adjusted for splits (1-for-20 overall). | Cover page 2026-11-10 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2026-07-06 | Source 2026-07-06 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-13 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-11-06 |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $6K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$8.6M | -$9.6M | $5.1M | No debt tags | $4.3M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $0 | -$24.2M | -$9.0M | $15.0M | No debt tags | $7.1M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $1.1M | $19.4M | -$6.4M | $5.1M | $0 | $9.4M | 10-K 2026-03-24 |
| Q3 2025 2025-09-30 | $3.2M | -$7.7M | -$5.6M | $9.1M | $7.0M | $11.7M | 10-Q 2025-11-06 |
| Q2 2025 2025-06-30 | $2.7M | -$8.6M | -$8.0M | $10.1M | $7.4M | $11.4M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $2.4M | -$10.6M | -$7.3M | $20.3M | $7.2M | $11.2M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $3.3M | -$9.6M | -$9.3M | $20.0M | $7.6M | $10.9M | 10-K 2026-03-24 |
| Q3 2024 2024-09-30 | $2.9M | -$10.1M | -$5.9M | $20.9M | No debt tags | $10.3M | 10-Q 2025-11-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2026-11-13 |
| Latest annual report | 10-K | 2026-03-24 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report FORM 8-K | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-11-02 |
Source: SEC EDGAR submissions feed, 1,029 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -50.5% |
| 1 month | -26.2% |
| 3 months | -75.9% |
| Year to date | -97.7% |
| 1 year | -98.0% |
| From 52-week high | -98.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LIMN | Liminatus Pharma Inc. | $2.97 | -0.67% | $4.0M |
| BTTC | Black Titan Corporation | $0.2873 | -9.20% | $4.3M |
| CELZ | Creative Medical Technology Holdings Inc. | $0.5201 | -1.51% | $4.0M |
| AIM | AIM ImmunoTech Inc. | $0.1310 | -8.77% | $5.2M |
| SNTI | Senti Biosciences Holdings Inc. | $0.1360 | -2.86% | $5.2M |
| VIVS | VivoSim Labs Inc. | $0.1237 | -2.68% | $2.5M |
| CLDI | Calidi Biotherapeutics Inc. | $0.6023 | -3.15% | $2.2M |
| INAB | IN8bio Inc. | $0.8160 | -0.49% | $8.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier